TWI306402B - N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy - Google Patents
N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy Download PDFInfo
- Publication number
- TWI306402B TWI306402B TW092109074A TW92109074A TWI306402B TW I306402 B TWI306402 B TW I306402B TW 092109074 A TW092109074 A TW 092109074A TW 92109074 A TW92109074 A TW 92109074A TW I306402 B TWI306402 B TW I306402B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- formula
- phenyl
- compound
- chloro
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 3
- FYAFZECZBPTDGS-UHFFFAOYSA-N n-[phenyl(piperidin-2-yl)methyl]benzamide Chemical class C=1C=CC=CC=1C(=O)NC(C=1C=CC=CC=1)C1CCCCN1 FYAFZECZBPTDGS-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 75
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- -1 1-mercaptohexahydropyridin-2-ylphenyl Chemical group 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003556 anti-epileptic effect Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 150000002923 oximes Chemical class 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 206010001584 alcohol abuse Diseases 0.000 claims description 2
- 208000025746 alcohol use disease Diseases 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- XBGXGCOLWCMVOI-UHFFFAOYSA-N 3-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC(C(F)(F)F)=C1 XBGXGCOLWCMVOI-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims 1
- LYJISYKJZLVGLG-UHFFFAOYSA-N 2-(trifluoromethyl)benzamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC=CC=C1C(F)(F)F LYJISYKJZLVGLG-UHFFFAOYSA-N 0.000 claims 1
- FQXQBFUUVCDIRK-UHFFFAOYSA-M 3-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-M 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 claims 1
- 230000009329 sexual behaviour Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- 239000000203 mixture Substances 0.000 description 52
- 239000000243 solution Substances 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 23
- 239000004471 Glycine Substances 0.000 description 18
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 16
- 238000002844 melting Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000007791 liquid phase Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- LZLSLGVFHCTZAH-UHFFFAOYSA-N 4-amino-3-chloro-5-(trifluoromethyl)benzoic acid Chemical compound NC1=C(Cl)C=C(C(O)=O)C=C1C(F)(F)F LZLSLGVFHCTZAH-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000001238 wet grinding Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 125000006327 phenyl hydrazinyl group Chemical group [H]N(*)N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229960004217 benzyl alcohol Drugs 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OSUIUMQSEFFIKM-WCCKRBBISA-N (2s)-2-amino-4-methylsulfanylbutanoic acid;hydrochloride Chemical compound Cl.CSCC[C@H](N)C(O)=O OSUIUMQSEFFIKM-WCCKRBBISA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- RSJDEVMJZLLAHS-OWBHPGMISA-N (NZ)-N-[phenyl(pyridin-2-yl)methylidene]hydroxylamine Chemical compound C(C1=CC=CC=C1)(/C1=NC=CC=C1)=N/O RSJDEVMJZLLAHS-OWBHPGMISA-N 0.000 description 1
- IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- IFZHGQSUNAKKSN-UHFFFAOYSA-N 1,1-diethylhydrazine Chemical compound CCN(N)CC IFZHGQSUNAKKSN-UHFFFAOYSA-N 0.000 description 1
- AEFBNJXWRHSZGO-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrene Chemical compound C1=C2CCCC(CC3)C2=C2C3=CC=CC2=C1 AEFBNJXWRHSZGO-UHFFFAOYSA-N 0.000 description 1
- PUNXVEAWLAVABA-UHFFFAOYSA-N 1,2,3,4-tetrahydroanthracene;1,2,5,6-tetrahydroanthracene Chemical compound C1=CC=C2C=C(CCCC3)C3=CC2=C1.C1=CCCC2=C1C=C1CCC=CC1=C2 PUNXVEAWLAVABA-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical group O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GRAKHOCSWNZIPQ-UHFFFAOYSA-N 1-decylpiperidine Chemical compound CCCCCCCCCCN1CCCCC1 GRAKHOCSWNZIPQ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- RMTHQMAFKOSFEB-UHFFFAOYSA-N 1-methyl-2,3,3a,4,5,6-hexahydroindole Chemical compound CN1CCC2CCCC=C12 RMTHQMAFKOSFEB-UHFFFAOYSA-N 0.000 description 1
- YAWCMQIRPKCWKO-UHFFFAOYSA-N 1-phenyl-1-(trifluoromethyl)hydrazine Chemical compound FC(F)(F)N(N)C1=CC=CC=C1 YAWCMQIRPKCWKO-UHFFFAOYSA-N 0.000 description 1
- UKZJZMLGGSGZMI-UHFFFAOYSA-N 2,3,4,7,8,9-hexahydro-1h-purine Chemical compound N1CNC=C2NCNC21 UKZJZMLGGSGZMI-UHFFFAOYSA-N 0.000 description 1
- NUUJBLHNDKOFOP-UHFFFAOYSA-N 2,3,4-tris(sulfanyl)benzoic acid Chemical compound OC(=O)C1=CC=C(S)C(S)=C1S NUUJBLHNDKOFOP-UHFFFAOYSA-N 0.000 description 1
- CLVIVSYJRYAYAB-UHFFFAOYSA-N 2-(fluoromethyl)benzenecarboximidamide hydrochloride Chemical compound Cl.NC(=N)C1=CC=CC=C1CF CLVIVSYJRYAYAB-UHFFFAOYSA-N 0.000 description 1
- AXOAWWUSRZCGKS-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1Cl AXOAWWUSRZCGKS-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- LAOZSCRCYVBSJA-UHFFFAOYSA-N 5,5-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CC1(C)C(=O)NC(=O)NC1=O LAOZSCRCYVBSJA-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1h-pyrazole Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- MAUVPXKHQPJZEG-UHFFFAOYSA-N C1=CC=C(C=C1)OC(C(=O)O)C(C(=O)O)(N=C(N)N)OC2=CC=CC=C2 Chemical compound C1=CC=C(C=C1)OC(C(=O)O)C(C(=O)O)(N=C(N)N)OC2=CC=CC=C2 MAUVPXKHQPJZEG-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 241000052343 Dares Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000086550 Dinosauria Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000019886 MethocelTM Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WFMRQEPYKQVDKS-UHFFFAOYSA-N [IH]1CCCCCCCC1 Chemical compound [IH]1CCCCCCCC1 WFMRQEPYKQVDKS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- VYXHQRRLAQJDGH-UHFFFAOYSA-N benzoic acid;dichloromethane Chemical compound ClCCl.OC(=O)C1=CC=CC=C1 VYXHQRRLAQJDGH-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- KCAFEQQLYHEUQK-UHFFFAOYSA-N decyl trifluoromethanesulfonate Chemical compound CCCCCCCCCCOS(=O)(=O)C(F)(F)F KCAFEQQLYHEUQK-UHFFFAOYSA-N 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- SZIKRGHFZTYTIT-UHFFFAOYSA-N ethyl piperidine-2-carboxylate Chemical compound CCOC(=O)C1CCCCN1 SZIKRGHFZTYTIT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- FRVCGRDGKAINSV-UHFFFAOYSA-L iron(2+);octadecanoate Chemical compound [Fe+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O FRVCGRDGKAINSV-UHFFFAOYSA-L 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- UZOAUVVPRBZUPQ-UHFFFAOYSA-N n,n-bis(sulfanyl)acetamide Chemical compound CC(=O)N(S)S UZOAUVVPRBZUPQ-UHFFFAOYSA-N 0.000 description 1
- YWWNNLPSZSEZNZ-UHFFFAOYSA-N n,n-dimethyldecan-1-amine Chemical compound CCCCCCCCCCN(C)C YWWNNLPSZSEZNZ-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- PRAYXGYYVXRDDW-UHFFFAOYSA-N piperidin-2-ylmethanol Chemical compound OCC1CCCCN1 PRAYXGYYVXRDDW-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- UPIXZLGONUBZLK-UHFFFAOYSA-N platinum Chemical compound [Pt].[Pt] UPIXZLGONUBZLK-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
1306402 攻、發明說明: 【發明所屬之技術領域】 本發明係揭示具醫療用途之式(I)化合物。 【先前技術】 在美國專利第5254569號中描述了具有與本發明之化合 物類似之結構的化合物,藉著作用在鴉片製劑(opiate)受體 上的機制,而作為止痛藥、利尿劑、抗痙攣劑、麻醉劑' 鎮靜劑、腦保護劑。在歐洲專利申請案第0499995號中,描 述其他具有與5-HT3拮抗劑類似之結構的化合物,其可用來 治療精神病之病症、神經學的疾病、胃徵候群、噁 心和口區
口 4*_ Q 【發明内容】 本發明之化合物相當於通式(工)
其中A代表 通式NI之基團,纟中〜代表氫原子,或直線或分支的 (Ci-C7)烷基基團,可視需要以—或多個氟原子取代,或 (G-C7)裱烷基基團,或(c^c?)環烷基烷基基團,或 苯基(CVC3)垸基基團’可視需要以一或多個經基或甲氧基 基團取代,或(C2-C4)稀基基图或(C2_C4)块基基團, 84443 1306402 或通式N + (〇-)Rl之基團,其中R,如同上文之定義, 或者是通式N^Ri)^之基團,其中R,代表直線或分支的 (C1-C7)燒基基團,且&如同上文之定義, X代表氫原子,或一或多個選自_素原子和三氟甲基、直線 或分支的(C1-C4)烷基和(C1-C4)燒氧基基團的取代基,尺2代 表氫原子、或一或多個選自鹵素原子和三氟甲基、(Ci_C4) 燒基或(Ci-C4)烷氧基基團,或通式NRsR4之胺基基團,其中 和R4(彼此獨立地)分別代表氫原子或(Ci_C4)烷基基團, 或與它們所攜帶的氮原子形成吡咯啶、六氫吡啶或嗎啉 %,或可視需要以根據針對上文符號χ所定義之原子或基團 取代之苯基基圑的取代基。 通式⑴之化合物可以蘇型(threo)消旋物之形式(1R,2R; IS,2S),或以對映體之形式(1R,2R)(1S,2S)存在;它們可 以自由鹼,或是帶有酸之加成鹽的形式存在。 在美國專利第52545 69號中描述了具有與本發明之化合 物頒似之結構的化合物,藉著作用在鴉片製劑(ο#"勾受體 上的機制,而作為止痛藥、利尿劑、抗痙攣劑、麻醉劑、 鎮靜劑、腦保護劑。在歐洲專利申請案第0499995號中,描 迟其他具有與5_HT3拮抗劑類似之結構的化合物,其可用來 療精神病之病症、神經學的疾病、胃徵候群、噁心和嘔 吐。 月之化合物在作為甘胺酸運載者glyU及/或glyC的 專抑制劑上,顯露出特殊的活性。 較適合作為glyti運載者 之抑制劑的化合物是具有組態(1 s, 84443 !3〇64〇2 2 S)的,其中&代表一或多個 二 囷京原子或三氟甲基基團,而 車父適合作為glyt2運載者之抑制劑的化合物是具有组態㈣, 叫的二其代代表自素原子和通式顺爪的胺基基團。 可藉著以下列之計書1解釋沾士、土 、 —郫釋的万法,來製備其中A代表通 式N-l之基團,其中汉盥氫 、虱席于不冋的通式(I)之化合物。 計畫1
R#H) 方法,將通式(II)之二胺(其中Ri 氫原子不同)),與活性酸或通式 釋離基,像是鹵素原子,且汉2如 使用熟諳此藝者已知的 和X如同上文之定義(心與 (ΠΙ)之醯基氯(其中Y代表 同上文之定義)偶聯。 來製備通式(II)之二 可藉著以下列之計畫2解釋的方法 胺。 84443 1306402 計畫2
(ID (ii)
使式(IV)之Weinreb醯胺與通式(V)之苯基鐘衍生物(其中 X如同上文之定義),在諸如二乙醚之類的醚溶劑中’在-30 °C到室溫之間反應;獲得通式(VI)之酮,利用還原劑,像 是 K-Selectride® 或 L-Selectride®(三-第二-丁基氫爛化 4甲或 鋰),在諸如四氫吱喃之類的醚溶劑中,在-7 81到室溫之 間,將其還原成具有蘇型组態之通式(VII)的醇。然後可藉 著合虱化物’像是氫化銘麵的作用’在諸如四氫吱喃之 類的醚溶劑中,在室溫到迴流溫度之間,還原通式(VII)之 胺基曱酸酉曰,成為通式(νιπ)之蘇型N_甲基胺基醇。然後在 兩個步驟中先藉著甲續酿氣的作用,在諸如二氣 之類氯,了的溶劑中,並在諸如三乙胺之類驗的存在下: 在〇c到至溫〈間’將醇官能基全部轉變為釋離基,例如甲 84443 1306402 烷磺酿酸酯基團,然後使該釋離基在_5(TC下,在諸如乙醇 之類的醇中,在_5〇r到室溫之間,在諸如高壓滅菌器之類 的密封介質中’與液化氨反應,將通式(VIII)之蘇型醇轉變 為通式(Π)之蘇型中間物,其中Rir表甲基基團。 亦可能藉著諸如含水氫氧化钾之類的強驗,在諸如甲醇 之類的醇中,將通式(VII)之胺基甲酸酯脫保護,以便獲得 通式(IX)之蘇型胺基醇,再藉著式RiZ之鹵化衍生物(其中 1如同上文之定義,但與氫原子不同,而2代表鹵素原子卜 在諸如碳酸鉀之類鹼的存在下,在諸如N,N_二曱基甲酿胺 之類的極性溶劑中,在室溫到10(rc之間,進行小烷基化作 用。然後按照關於通式(VIII)之醇的描述,處理如此獲得的 通式(X)之醇。 藉著下列的計畫3解釋其他不同的方法,計畫3可用於其 中心代表甲基基團,且X代表氳原子的案例中。藉著例如三 氟甲烷磺酸曱酯的作用,在諸如二乙醚之類的醚溶劑中, 在室溫下,將式〇〇)之吡啶肟四級化。然後在氫氣壓下, 使如此獲得的式(XII)吡錠鹽, 計畫3
在醇和含水酸,像是 在諸如氧化鉑之類催化劑的存在下 84443 • 11 - 1306402 乙醇和1N氫氯酸的混合物中,接受氫化作用。獲得兩種非 對映異構物蘇型/赤型(erythroWn之混合物形式的通式 之二胺,其中心代表甲基基團,而χ代表氫原子。可能使其 成鹽,例如利用草酸,然後藉著從醇和醚溶劑,像是甲醇 和二乙醚之混合物中形成草酸鹽的再結晶作用純化,如此 獲得純的蘇型非對映異構物(1R,2R; 1S,2S)。 可藉著以下列之計畫4解釋的方法,來製備其中A代表通 式NR!之基團,其中Ri代表氫原子的通式⑴之化合物。 計晝4
從通式(ΧΠΙ)之胺開始,其中χ如同上文之定義’根據熟 磺此藝者已知的方法,進行與如同上述之通式(III)之活性 酸或醯基氯的偶聯作用,以便獲得通式(χιν)之化合物。最 後,進行後者的氫化作用,例如,利用氫,在諸如5%披鉑 厌之類催化劑的存在下,在諸如冰醋酸之類的酸性溶劑 中,如此終於獲得通式⑴之化合物,其中Ri代表氫原子。 根據計畫2,其他方法包括使用通式⑴之化合物,其中Ri 代表可視需要經取代的苯甲基基團,並將六氫吡啶環之氮 脫保護,例如利用氧化劑,或利用諸如三溴化硼之類的路 易斯酸,或藉著氫解作用,或是烯基基團,最好是烯丙基 84443 -12- 1306402 基團’接:f以PdQ複合物脫保護,以便獲得通式⑴之化合 物’其中心代表氫原子。 可仗其中A代表通式n_Ri(其中心如同上述)之基團的通 式⑴< 化合物,來製備其中A代表通SN+(a)Ri之基團的通 式⑴之化合物’藉著使其與氧化劑,例如3_氯過苯甲酸, 在諸如二氯甲烷之類的氯化了的溶劑中,在〇t到室溫之間 的溫度下反應。 可從其中A代表通式N-1之基團的式⑴化合物,來製備 其中A代表通式矿(Ri)Ri之基團的式⑴化合物,藉著使其與 通式R ·Ζ之基自,其中R,如同上文之定義,且冗代表鹵素 原子,在诸如乙腈之類的極性溶劑中,在室溫到丄〇〇。〇之間 的溫度下反應。 此外,亦可藉著以高效液體層析(HPLC),在手性管拄上 分離消旋化合物,或藉著使用手性酸,像是酒石酸、樟腦 %酸、二苯曱醯基酒石酸、N_乙醯基亮胺酸,拆開通式(π) 之消旋胺,從醇型的溶劑中,藉著非對映異構之鹽的分級 和選擇性再結晶作用,或藉著根據計畫2的對映選擇性合 成’使用通式(IV)之手性Weinreb醯胺,獲得相當於蘇型非 對映異構物之對映體(1R,2R)4(1S,2S)的通式⑴之手性化 合物。 可根據類似在Eur. J. Med. Chem.,35,(2000),979-988和 J. Med· Chem·,41,(1998),591-601中描述的方法,製備式(IV) I消旋或手性Weinreb醯胺。其中X代表氫原子的通式(V)之 苯基經化合物是可購得的。可根據類似在丁以^. Lett.,57, 33, 84443 •13- 1306402 (1996),59G5·测中描述的方法,製備其經取代之衍生物。 [IaCUna]係根據類似在歐洲專财請案㈣366刪號中描述 的万法。纟中X代表氫原子的通式(ίχ)之胺,可在根據在美 國專利第US-2928835號中描述之方法的手性系列中製備。 最後,通式(XIII)之胺,可根據類似在Chem pharm Buu,32, 12,(1984),4893-4906和Synthesis,(1976),593-595 中描述的 方法來製備。 除了在4-胺基-3-氯-5-三氟甲基苯甲酸的案例中,通式 (III)之酸和醯基氯均是市售的。可藉著根據類似在Arzneim.
Forsch.,34, lla,(1984),1668-1679 中描述的方法,在諸如氯 仿之類的氯化了的溶劑中,以磺醯氯氯化4_胺基_5_三氟曱 基苯甲酸,來製備4-胺基-3-氯-5-三氟甲基苯曱酸。 實例接下來解釋本發明的數個化合物的製備。初步的微 量分析和IR與NMR光譜,以及在手性管柱上的Ηριχ,證實 所獲得之化合物的結構和對映體純度。 在實例開頭以括弧表示的編號,代表在稍後提供之表 中,第一攔的那些。 在化合物的名稱中,破折號形成字的—部分,而破折 號僅在線的末端用來分割;其在缺乏分割時被刪除,且 不應以正常的破折號或以間隙來代替。 【實施方式】 實例1(化合物第33號) 蘇-2 -氯-N-[(l -乙基六氫p比咬-2-基)苯曱基]三氣甲基苯 甲醯胺鹽酸鹽1:1 84443 -14· 1306402 1.1. 2-苯甲醯基六氫吡啶羧酸込丨-二甲乙酯 在氬氣壓下,將在1〇〇毫升無水二乙瞇中之8〇克(29.4毫 莫耳)的2-(N-甲氧基曱基胺甲醯基)六氫吡啶羧酸 M-二曱乙酯,導入250毫升的圓底燒瓶,將介質冷卻至_25 C,逐滴加入16¾升(29.4毫莫耳)在環己烷和二乙醚之 70/30 w合物中的1 8M苯基鋰溶液,並保持攪拌2小時。 在利用飽和含水的氯化鈉溶液水解之後,分離液相,以 醋酸乙酯萃取,將有機相覆以硫酸鈉脫水,將其過濾,在 降低的壓力下濃縮濾液,並在矽膠管柱上藉著層析法純化 殘餘物,以醋酸乙酯和環己烷的混合物洗脫。 獲得2克的白色固體。 1·2·蘇-[羥基(苯基)曱基]六氫吡啶_丨_羧酸u-二曱乙酯 在氬氣壓下,將在30毫升無水二乙醚中之2.〇克(69毫莫 耳)2_苯甲醯基六氫吡啶-1-羧酸U-二曱乙酯導入250毫升 圓底燒瓶中,將該溶液冷卻至_78t,逐滴加入2〇7毫升 (2〇.7耄莫耳)在二乙醚中的1M三-第二丁基硼氫化鋰溶液, 並保持攪拌3小時。 以16¾升水和16毫升35%含水的過氧化氫溶液水解該混 &物’並谷§午該混合物回到室溫’同時攪拌2小時。 以水和醋酸乙酯稀釋,分離液相,並以醋酸乙酯萃取。 在沖洗混合的有機相之後,覆以硫酸鈉脫水,並在降低的 壓力下蒸發溶劑,在矽膠管柱上藉著層析法純化殘餘物, 以醋酸乙酯和環己烷的混合物洗脫。 獲得2.0克的油狀產物。 84443 -15- ^3〇64〇2 ·3·蘇-苯基(六氫峨咬_2_基)甲醇 將在40毫升甲醇中之2_〇克(6.9毫莫耳)蘇_[羥基(苯基).甲 基]六氫吡啶-1-羧酸1,1-二甲乙酯的溶液,放到25〇毫升圓底 繞瓶中,加入從2克氫氧化鉀小珠和2〇亳升水製備的含水氫 氧化鉀溶液’並在迴流下將該混合物加熱2小時。 冷卻該混合物,在降低的壓力下蒸發掉溶劑,加入水, 並以二氯甲烷萃取該混合物數次。在沖洗混合的有機相之 後,覆以硫酸鎂脫水,過濾並在降低之壓力下蒸發溶劑, 獲得1克的白色固體。 熔點:172-174°C。 14·蘇-(1-乙基六氫吡啶_2_基)苯基甲醇 將在30毫升無水N,N-二甲基曱醯胺中之1克(5 2毫莫耳) 蘇-苯基(六氫吡啶-2-基)甲醇的溶液,放到1 〇〇毫升圓底燒 瓶中,加入0.39毫升(5.2毫莫耳)溴乙烷和〇8克(5.8毫莫耳) 碳酸鉀,並將該混合物加熱至8〇它2小時。將其冷卻至室 溫,藉著加入水將其水解,並以醋酸乙酯萃取數次。在以 水,然後以飽和含水的氯化鈉溶液沖洗混合的有機相之 後,覆以硫酸鎂脫水,過濾並在降低之壓力下蒸發溶劑, 在石夕膠管柱上藉著層析法純化殘餘物,以二氣甲燒和甲醇 的混合物洗脫。獲得0.8克的油狀化合物。 1 · 5 ·穌_ - (1 乙基7T氣p比咬-2 -基)苯基甲娱^胺 在氬氣壓之下,將在20毫升無水二氯甲烷中之〇8克(3.65 愛莫耳)蘇-(1-乙基六氫吡啶-2-基)苯基甲醇和〇 48毫升 (3.65毫莫耳)三乙胺,導入1〇〇毫升圓底燒瓶中,將該混合 84443 -16- 1306402 物冷卻至o°c 加入0.28毫升(3.63毫莫耳)甲烷磺 容許該混合物慢慢地回到室溫2 縮0 醯氣,並 小時,並在降低的壓力下.濃 將液化氨導人提供雜料的高壓減菌器巾,並冷卻至 -5(TC,加入在10毫升絕對乙醇中,事前製備之甲烷磺酸酿 的溶液’關閉該高壓滅菌器’並保持_48小時。 將該混合物移至圓底燒瓶’在降低的壓力下將主濃·, 並在碎膠管柱上藉著層析法純化殘餘物,以二氯甲燒和甲 醇的混合物洗脫。 個步驟中使用這樣的油 獲得〇_3克的油狀化合物,在下— 狀化合物。 1.6.蘇-2-氯-N-[(l-乙基六 基苯曱醯胺鹽酸鹽1:1 氫吡啶-2-基)苯曱基]_3_三氟甲 將在1〇毫升二氯甲燒中之〇.3克(137毫莫耳)2_氣小三氣 曱基苯曱酸、0.26克(1.37毫莫耳二甲胺基)丙基]·^ 乙基礙化二醢亞胺和〇.19克(1.37毫莫耳)K#i基苯并三也的 溶液’加至50毫升圓底燒瓶中,並在室溫下揽拌該混合物 3 0分鐘。 加入在數毫升二氯甲垸中之〇.3克(137毫莫耳)蘇_(1_乙 基六氫吡啶-2-基)苯基甲烷胺的溶液,並繼續攪拌5小時。 以水將該混合物水解,並以二氣甲烷萃取數次。在以水, 然後以⑺含水的氯氧化納溶液沖洗有機相之後,覆以硫酸 鎂脫水,《並在降低的壓力下蒸發溶劑,並在树管柱 上藉著層析法純化殘餘物,以二氯甲垸和甲醇的混合物洗 84443 -17- 1306402 脫。 獲得0 · 2 5克的油狀產物。 將產物溶解於數毫升丙_2_醇中,加入5_9亳升在丙_2_醇 中的0.1Ν氫氯酸溶液,並在降低的壓力下濃縮該混合物, 以便減少溶劑的體積。在濕磨之後,最後分離出白色固體 形式的0.15克鹽酸鹽。 熔點:230-232°C。 實例2(化合物第18號) 2-氯-N-[(1S)-[(2S)-1-曱基六氫吡啶基]苯甲基卜3_三氟 甲基苯曱醯胺鹽酸鹽1:1 2.1. (2S)-2-本曱醯基穴氫p比咬-1_幾酸1,1_二曱乙酉旨 在氮氣壓下’將在100¾升無水二乙醚中之11.8克(43.3毫 莫耳)的(2S)-2-(N-甲氧基-N-甲基胺曱醯基)六氫吡啶羧 酸1,1-二曱乙酯,導入500毫升的圓底燒瓶,將介質冷卻至 -23°C,逐滴加入21_6毫升(43.2毫莫耳)在環己烷和二乙醚之 70/30混合物中的1.8M苯基鋰溶液,並在室溫下攪拌該混合 物3小時。 在利用飽和含水的氯化鈉溶液水解之後,分離液相,並 以醋酸乙酯萃取。將有機相覆以硫酸鈉脫水,過遽,在降 低的壓力下濃縮,並在矽膠管柱上藉著層析法純化殘餘 物,以醋酸乙酯和環己烷的混合物洗脫。 獲得4.55克的固體產物。 熔點:123-125°C。 focp =-25.40(c=2.22; CH2Cl2) ee=97_2%。 84443 -18- 1306402 2·2. (lS)-2-[(2S)-羥基(苯基)甲基]六氫吡啶-;!_羧酸^•二 曱乙酯 在氮氣壓下’將在170毫升無水四氫吱喃中之4.68克(16.2 Φ莫耳)(2S)-2 -苯甲醯基六氫?比淀-1_羧酸ι,ι_二曱乙醋導 入500毫升圓底燒瓶中,將該溶液冷卻至_78。〇,逐滴加入 48.5毫升(4 8_5毫莫耳)在四氫呋喃中的iM L-Selectride® (三-第二-丁基硼氫化鋰)溶液,並在室溫下攪拌該混合物5 小時。 在冰冷的狀態下,以34毫升水和34毫升35%含水的過氧 化氫溶液慢慢地水解該混合物,並容許其回到室溫,同時 授拌2小時。 以水和酷酸乙g旨稀釋,分離液相’並以酷酸乙酿萃取。 在沖洗混合的有機相之後’覆以硫酸鈉脫水,過滤並蒸發, 在石夕膠管柱上藉著層析法純化殘餘物,以醋酸乙醋和環己 烷的混合物洗脫。 獲得4·49克淡黃色的油。 峨=+63.75°(c=0.8; CH2C12) ee=97.8%。 2.3. (1S)-[(2S)-(1-甲基六氫u比淀-2-基)]苯基甲醇 在氮氣壓下,將在50毫升無水四氫吱喃中之2.96克(7 8.1 毫莫耳)的氫化鋁鋰導入200毫升的二·頸燒瓶中,在迴流下 加熱該混合物,加入在35毫升四氫呋喃中之4.49克(15.4毫 莫耳)的(lS)-2-[(2S)-經基(苯基)甲基]六氫峨咬卜叛酸ι,ΐ-二甲乙酯’並將該混合物保持在迴流下3 _ 5小時。 將其冷卻,利用〇. 1Μ的酒石酸鈉4甲溶液慢慢地水解,並 84443 •19- 1306402 持續攪拌該混合物過夜。 將其過濾,並以四氫呋喃沖洗沉澱物,然後在降低的壓 力下濃縮濾液。 獲得2.9 5克無色油狀的產物。 2_4. (1S)-[(2S)-(1·曱基六氫吡啶_2•基苯基甲烷胺 在氮氣壓下,將在70毫升中之2.95克(14.4毫莫耳)的 (1S)-[(2S)_(1-甲基六氫峨淀_2_基)]苯基曱醇,和2毫升(丨44 寬莫耳)的二乙胺,導入250毫升的圓底燒瓶中,將介質冷 卻至0C,加入1.1¾升(14_4毫莫耳)的曱烷磺醯氣,容許該 混合物在2小時内慢慢地回到室溫,並在降低的壓力下濃 縮。 將液化氨導入提供磁性攪拌的高壓滅菌器中,並冷卻至 -50 C,加入在30毫升絕對乙醇中,事前製備之粗製甲烷磺 酸酯的溶液,關閉該高壓滅菌器,並保持攪拌48小時。 將該混合物移至圓底燒瓶,並以油狀產物之形式分離 胺,在下一個步驟中使用這樣的胺。 2.5. 2-氯-]>1-[(18)-[(28)-1-曱基六氫峨淀_2-基]苯曱基]-3-三 氟甲基苯甲醯胺鹽酸鹽1:1 使用在1.6點中描述的程序,從〗克(49毫莫耳)2_氯_3-三 氟甲基苯甲酸、〇·9克(4.9毫莫耳)1-[3-(二甲胺基)丙基]-3-乙基碳化二醯亞胺鹽酸鹽、〇66克(46毫莫耳)卜羥基苯并三 唑和1克(4.9毫莫耳)(1S)_[(2SH1_甲基六氫吡啶_2_基)]苯 基甲燒胺開始,在矽膠管柱上藉著層析法純化,以二氯甲 烷和甲醇的混合物洗脫之後,獲得〇 45克鹼形式的產物。 84443 •20- 1306402 將產物溶解於數毫升丙-2-醇中,加入ι〇·9毫升在丙-2-醇 中的1N氩氯酸溶液,並在降低的壓力下濃縮該混合物,.以 便減少溶劑的體積。 在濕磨之後,最後分離出白色固體形式的0.37克鹽酸鹽。 熔點:230-232°C。 =+70.3°(c=0.825; CH3OH) ee=>99% = 實例3(化合物第24號) 蘇-4-胺基-3-氯-正-[(1-甲基六氫吡啶_2_基)苯甲基]_5_三氟 甲基苯甲醯胺鹽酸鹽1:1 3.1. 2-(卞氧亞胺基苯甲基)_丨_甲基吡錠三氟甲烷磺酸酯 在0C下’將17.4毫升(120毫莫耳)的三氟甲烷磺酸甲酯, 逐滴加入在200毫升二乙醚中之35克(12〇毫莫耳)苯基(吡啶 -2-基)甲酮〇-卞肪的懸浮液中,並在室溫下攪拌該混合物3 小時。 藉著過濾回收所形成的沉澱物,並在降低的壓力下將其 脫水。 ^ 獲得49克的產物,在下一個步驟中使用這樣的產物。 3.2·蘇-(1_甲基六氫吡啶-2-基)苯基甲烷胺乙二酸酯2:1 一將在5〇毫升乙醇和50毫升1N氫氣酸中的14.8克(31.89毫 莫耳氧亞胺基苯〒基)小甲基賴三氟甲垸魏酉旨和 〇·74克氧錢,放至帕爾(ρ_燒瓶中,並進行氫化作用$ 在降低的壓力下蒸發乙醇, 離液相,在其中加入氨水溶液 以一氯甲燒萃取殘餘物,分 ,並以二氣甲烷萃取。在沖 84443 -21 - 1306402 洗混合的有機相之後,覆以硫酸制脫水,過遽並在降低的 塵力下蒸發溶劑,獲得6.7克油狀產物,包括lQ%赤型非 映異構物》 藉著將這些6.7克的鹼溶解於甲醇中,藉著溶解於最少量 曱醇中之二當量乙二酸的作用,製備乙二酸酯。 藉著從甲醇和二乙醚之混合物中的再結晶作用,純化所 獲传的鹽。 最後分離出4_7克之蘇型非對映異構物的純乙二酸酯。 熔點:156-159。(:。 3.3. 4-胺基-3-氯-5-三氟甲基苯甲酸 在9.97¾升(50¾莫耳)%酿氣的存在下,將在毫升氣仿 中之7.8克(40毫莫耳)的4-胺基-5-三氟曱基苯曱酸,放在5〇〇 毫升的圓底燒瓶中’並在迴流下攪拌該混合物過夜。 在降低的壓力下蒸發溶劑,將殘餘物溶解於水和氨水 中’並以二氣甲烷萃取該混合物。將液相酸化,藉著過濾 回收所形成的沉澱物,並在降低的壓力下脫水。 獲得9克的產物。 熔點:229-235。(:。 3· 4.蘇-4-胺基-3-氯-N-[(l-甲基六氫ϋ比淀-2-基)苯甲基]-5-三氟甲基苯曱醯胺鹽酸鹽1:1 將在5毫升1,2-二氯乙烷中之0.52克(2.15毫莫耳)4-胺基 -3-氯-5-三氟甲基苯甲酸、0.37克(1.96毫莫耳)1-[3-(二甲胺 基)丙基]-3-乙基碳化二醯亞胺鹽酸鹽、0.26克(1.96毫莫 耳)丨-羥基苯并三唑,放到100毫升圓底燒瓶中,並在室溫下 84443 -22- 1306402 攪掉該混合物10分鐘。加入在5毫升12_二氣乙烷中之0.4克 (、1·96毫莫耳)蘇_(1_曱基六氫吡啶_2_基)苯基甲烷胺的溶 & ’並繼續攪拌該混合物12小時。 以水將其水解,加入氫氧化鉀小球,直到獲得鹼性的阳 值為止H氣曱料取該混合物。以水沖洗有機相, 覆以硫酸鈉脫水,過濾,在降低的壓力下蒸發溶劑,並在 矽膠管柱上藉著層析法純化殘餘物,以二氯甲烷和甲醇的 混合物洗脫。 分離出0.4克驗形式的化合物。 將其溶解於數毫升的丙_2_醇中,加入94毫升在丙-醇 中HN的氫氯酸溶液,並在降低的壓力下蒸發溶劑。收 集殘餘物’並在真空下脫水。 獲得0.285克的固體產物。 熔點:270-272Χ:。 fAl(化合物第25號) 4胺基-3-氣-N-[(1R)-[(2R)-1-甲基六氫?比咬_2_基]苯甲 基]-5-三氟甲基苯甲醯胺鹽酸鹽1:ι 4_1· (lR)-[(2RHl-f基六氫吡啶_2_基)]苯基甲烷胺 將在300毫升甲醇中之8〇克(39〇毫莫耳)蘇_〇-甲基六氫 吡啶_2-基)苯基甲烷胺的溶液,和在450毫升甲醇中之68克 (390¾莫耳)N_乙醯基_D_亮胺酸的溶液,導入4公升圓底燒 瓶中。在降低的壓力下濃縮該溶液,並使殘餘物從ιι〇〇毫 升的丙-2醇中再結晶。獲得72克(111)_[(211)_(1_曱基六氫吡 唉-2-基)]苯基甲烷胺的鹽類。 84443 •23- !3〇6402 重覆再結晶作用三次,而最後獲得 基六氳p比途-2-基)]苯基甲烷胺的鹽。 熔點:171.5°C。 砂=-ll0(c = l; CH3OH) ee>99%。 4·2· 4-胺基-3-氯甲基六氫吡啶_2•基)苯甲 基]_5·三氟曱基苯甲醯胺鹽酸鹽1:1 使用上文在3.4點中描述的程序’從丨04克(4.37毫莫耳)4_ 胺基-3-氯-5-三氟甲基苯甲酸、〇46克(3 97毫莫耳(二 甲胺基)丙基]-3-乙基碳化二醯亞胺鹽酸鹽、〇·53克(3 97毫 莫耳)1-羥基苯并三唑和L5克(3.97毫莫耳)的(111)_[(211)_曱 基π氫吡啶-2-基]苯基甲烷胺的鹽,獲得112克鹼形式的產 物0 藉著將28.2毫升在丙_2_醇中之〇_1Ν的氫氯酸溶液加至在 數毫升丙-2-醇中之L12克鹼的溶液中,來製備其鹽酸鹽。 在降低的壓力下蒸發溶劑,收集所獲得的固體,並在降低 的壓力下脫水。 最後分離出0.9克白色固體形式的鹽酸鹽。 熔點:175-1以。(:。 岐=+18.40(c=〇.〇91; CH3OH) ee=97_8%。 實―倒(化合物第36號) 蘇-2-氣-N-[苯基(六氫吡啶_2_基)甲基]_3_三氟曱基苯甲醯 胺鹽酸鹽1:1 5.1. 2-氯-N-[苯基卜比啶_2-基)曱基]-3_三氟甲基苯曱醯胺 將在60毫升二氯甲烷中之1_61克(7_16毫莫耳)2_氣_3_三 84443 -24· 1306402 氟甲基苯甲酸、1.4克(7.28毫莫耳)l-[3-(二甲胺基)丙基]_3_ 乙基碳化二醯亞胺鹽酸鹽、0.218克(1.79毫莫耳)4-二曱胺基 吡啶的溶液,放到250毫升圓底燒瓶中,並攪拌該混合物15 分鐘,加入在60毫升二氣曱烷中之ι·ι克(5.97毫莫耳)苯基 (峨啶-2-基)曱烷胺的溶液,並在室溫下攪拌該混合物24小 時。 藉著加入水將其水解,加入35%含水的氫氧化鈉溶液, 分離有機層’以水然後以飽和含水的氯化鋼溶液沖洗,覆 以硫酸鎂脫水,過濾並在降低的壓力下蒸發溶劑。在矽膠 S柱上藉著層析法純化殘餘物,以二氯甲燒和甲醇的混合 物洗脫,而最後分離出丨.34克黃色油形式的產物,其形成 結晶’並在下一個步驟中使用這樣的產物。 5_2.蘇-2-氣-N-[苯基(六氫吡啶_2_基)甲基]_3_三氟曱基苯 甲醯胺鹽酸鹽1:1 將在43毫升冰醋酸中之417克(1〇毫莫耳)2_氯_义[苯基 (吡哫-2-基)曱基]-3-三氟曱基苯甲醯胺的溶液放在帕爾燒 瓶中,加入0_1克50/。的披鉑炭,並在5(rc,〇 35Mpa下進行 氫化作用3小時。 在回到立恤之後,藉著過濾移除催化劑,在降低的壓力 下很縮濾液,將殘餘物溶解於水和醋酸乙酯中,加入濃縮 的虱氧化鈉,並以醋酸乙酯萃取該混合物數次。以水然後 乂飽和含水的氯化鈉溶液沖洗有機相,覆以硫酸鈉脫水, 過遽並在降低的壓力下蒸發H在輕管柱上藉著兩次 連續的層析法純化殘餘物,α二氯甲燒和曱醇的⑽/0至 84443 -25· 1306402 95/5混合物洗脫,以便分離未反應的起始物質。 分離出0 · 8克(較少極性)的蘇型非對映異構物。藉著將其 溶解於數毫升的丙-2-醇中,並在其中加入2〇毫升在丙-2_ 醇中之0.1N氫氣酸的溶液,來製備其鹽酸鹽。在降低的壓 力下部分地蒸發溶劑,藉著濕磨獲得白色的固體,藉著過 滤收集’並在降低的壓力下脫水。 最後獲得0.6克的鹽酸鹽。 熔點:234-235。(:。 f.例公化合物第37號) 2-氯-N-[(S)-苯基-[(2S)-六氫吡啶_2_基]甲基]_3_(三氟甲基) 苯甲醯胺鹽酸鹽1:1 將在100毫升無水二氯甲烷中之8 36克(3當量)丨,%二甲基 巴比妥酸的溶液,導入500毫升提供磁性攪拌、氬氣循環和 冷凝器的二-頸燒瓶中。加入〇.2克(0.01當量)的四價(三苯膦) 在巴’並將該反應介質加熱至3 5 °C。 加入7.8克(19.18毫莫耳)N-[(SH(2_SH•埽丙基六氫吡啶 -2-基](苯基)甲基]-2-氯-3-(三氟甲基)苯甲醯胺(根據類似實 例1之程序獲得)的溶液,並藉著薄層層析法監视反應的進 行。加入100毫升飽和的碳酸氫鈉溶液,在沉降之後分離介 質’並以100毫升二氯甲烷萃取液相,以1〇〇毫升水,然後 以1 00毫升飽和的氯化鈉溶液沖洗混合的有機相。將其覆以 硫酸鈉脫水,過濾並在降低的壓力下蒸發溶劑。 獲得10.15克灰褐色的固體,在矽膠管柱上藉著層析法純 化該固體’以含有0.4%之33%氨溶液的二氣子烷之混合物 84443 -26- 1306402 (23)-2[(13)-[[2-氯-3-(三氟甲基)苯甲醯基]胺基](苯基)甲 基]-1,1 -二甲基六氫57比錠硤 將在20¾升乙腈中之0.15克(0.36毫莫耳)2-氯-N-[(l S)_ [(2S)-1-曱基六氫吡啶-2-基]苯曱基]_3·三氟甲基苯曱醯胺 的溶液,導入50毫升提供磁性攪拌、氬氣循環和冷凝器的 二-頸燒瓶中,加入〇_5毫升碘曱烷,並將該介質加熱至 °C 2小時。 將蔹反應介質 壓力下脫水。 分離出0.17克的黃色固體。 熔點:121-123°C。 下列的表1解釋了本發明數個化合物的化學結構。 在”A"攔位中,咖5代表環丙基基團。在”cf3"搁位中 =通式⑴中CF3基围的位置。在” R2"搁位中, t基基團°在™中’”,,代錢狀態的化合物,”⑽ 代表鹽酸鹽,而"tfa,,代表三氟乙酸鹽。 表2解釋了數個化合物 切的物理特性、熔點和光學旋轉。 84443 -28- 1306402 表1
編號 立體化學 A X cf3 r2 鹽 1 蘇(1R,2R;1S,2S) n-ch3 H 6 2-F, 3-C1 HC1 2 蘇(1R,2R;1S,2S) n-ch3 H 2 4-CF3 HC1 3 蘇(1R,2R;1S,2S) n-ch3 H 2 6-CF3 HC1 4 蘇(1R,2R;1S,2S) n-ch3 H 2 5-C1 HC1 5 蘇(1R,2R;1S,2S) n-ch3 H 2 4-F - 6 蘇(1R,2R;1S,2S) n-ch3 H 2 5-CF3 - 7 蘇(1R,2R;1S,2S) n-ch3 H 2 3-C1 HC1 8 蘇(1R,2R;1S,2S) n-ch3 H 4 2,6-Cl2 HC1 9 蘇(1R,2R;1S,2S) n-ch3 H 4 2-C1 HC1 10 蘇(1R,2R;1S,2S) n-ch3 H 4 3-C1 HC1 84443 -29- 1306402 編號 立體化學 A X cf3 r2 m 11 蘇(1R,2R;1S,2S) n-ch3 H 3 4-F HC1 12 蘇(1R,2R;1S,2S) n-ch3 H 3 H HC1 13 蘇(1R,2R;1S,2S) n-ch3 H 5 2-C1 HC1 14 (1S,2S) n-ch3 H 5 2-C1 HC1 15 (1R,2R) n-ch3 H 5 2-C1 HC1 16 蘇(1R,2R;1S,2S) n-ch3 H 3 5-CF3 HC1 17 蘇(1R,2R;1S,2S) n-ch3 H 3 2-C1 HC1 18 (1S,2S) n-ch3 H 3 2-C1 HC1 19 (1R,2R) n-ch3 H 3 2-C1 HC1 20 蘇(1R,2R;1S,2S) n-ch3 H 3 4-C1 HC1 21 蘇(1R,2R;1S,2S) n-ch3 H 5 2-F, 3-C1 - 22 蘇(1R,2R;1S,2S) n-ch3 H 5 2-F - 23 蘇(1R,2R;1S,2S) n-ch3 H 5 2-OCH3, HC1 4-C6H5 24 蘇(1R,2R;1S,2S) n-ch3 H 5 3-C1, HC1 4-NH2 25 (1R,2R) n-ch3 H 5 3-C1, HC1 4-NH2 26 蘇(1R,2R;1S,2S) n-ch3 2-CH3 3 2-C1 HC1 . 27 蘇(1R,2R;1S,2S) n-ch3 H 3 2,6-Cl2 HC1 28 (1S,2S) n-ch3 H 3 2,6-Cl2 HC1 29 蘇(1R,2R;1S,2S) n-ch3 4-F 3 2-C1 HC1 84443 -30- 1306402 編號 立體化學 A X cf3 r2 鹽 30 (1S,2S) n-ch3 4-F 3 2-C1 HC1 31 (1S,2S) n-ch3 4-C1 3 2-C1 HC1 32 (1S,2S) n-ch3 4-C(CH3)3 3 2-C1 tfa 33 蘇(1R,2R;1S,2S) N-CH2CH3 H 3 2-C1 HC1 34 (1S,2S) N-CH3 4-CH3 3 2-C1 HC1 35 蘇(1R,2R;1S,2S) N-CH3 H 2 4-C1 HC1 36 蘇(1R,2R;1S,2S) NH H 3 2-C1 HC1 37 (1S,2S) NH H 3 2-C1 HC1 38 (1R,2R) NH H 3 2-C1 HC1 39 蘇(1R,2R;1S,2S) N-CH2CH(CH3)2 H 3 2-C1 HC1 40 (1S,2S) n-ch2ch(ch3)2 H 3 2-C1 HC1 41 蘇(1R,2R;1S,2S) N-(CH2)2CH3 H 3 2-C1 HC1 42 (1S,2S) N-(CH2)2CH3 H 3 2-C1 HC1 43 (1S,2S) n-ch2Cc3h5 H 3 2-C1 HC1 44 蘇(1R,2R;1S,2S) N-CH3 H 3 2-CH3 HC1 45 (1S,2S) n-ch(ch3)2 H 3 2-C1 HC1 46 (1S,2S) N-(CH2)3CH3 H 3 2-C1 HC1 47 (1S,2S) n-ch2c=ch H 3 2-C1 HC1 48 (1S,2S) n-ch2c6h5 H 3 2-C1 HC1 84443 -31 1306402 編 號 立體化學 A X cf3 r2 鹽 49 (1S,2S) N-CH2[3,4-(OCH3)2C6H3] H 3 2-C1 - 50 蘇(1R,2R;1S,2S) n-ch3 H 5 2-CH3 HC1 51 蘇(1R,2R;1S,2S) N-(CH2)3CF3 H 3 2-C1 HC1 52 (1S,2S) N-(CH2)2CH3 H 3 2-CH3 HC1 53 蘇(1R,2R;1S,2S) N-(CH2)2CH3 4-F 3 2-CH3 HC1 54 蘇(1R,2R;1S,2S) N-(CH2)2CH3 4-F 3 2-C1 HC1 55 蘇(1R,2R;1S,2S) N-(CH2)2CH3 4-C1 3 2-C1 HC1 56 蘇(1R,2R;1S,2S) N-(CH2)2CH3 4-C1 3 2-CH3 HC1 57 (1S,2S) n-ch3 H 3 2-CH3 HC1 58 (1S,2S) N-(CH2)2CH3 4-F 3 2-C1 HC1 59 蘇(1R,2R;1S,2S) n-ch2ch=ch2 H 3 2-C1 HC1 60 (1S,2S) n-ch2ch=ch2 H 3 2-C1 HC1 61 (1S,2S) NH H 3 2-CH3 HC1 62 (1S,2S) NH H 6 2- F, 3- C1 HC1 63 (1S,2S) NH H 5 2-C1 HC1 64 蘇(1R,2R;1S,2S) NH H 2 4-CF3 HC1 65 蘇(1R,2R;1S,2S) NH H 3 H HC1 66 蘇(1R,2R;1S,2S) NH H 3 2-F HC1 67 蘇(1R,2R;1S,2S) NH H 3 5-CF3 HC1 84443 -32- 1306402 編號 立體化學 A X cf3 r2 鹽 68 蘇(1R,2R;1S,2S) NH H 2 5-CF3 HC1 69 蘇(1R,2R;1S,2S) ^(OOCHs H 3 2-C1 HC1 70 蘇(1R,2R;1S,2S) N+(0')CH3 H 3 2-C1 HC1 71 (1S,2S) n+(ch3)2 H 3 2-C1 HC1 化合物第69號:最高極性的非對映異構物 化合物第70號:最低極性的非對映異構物 表2 編號 熔點(°C) [αΒ5 1 >270 - 2 152-154 - 3 >285 4 275-276 - 5 51-52 - 6 169 - 7 228-229 - 8 287-288 - 9 84-86 - 10 187-191 11 237.5-238.5 - 12 174-176 - 13 229-231 - 84443 -33- 1306402 編號 熔點(°C) kxF 14 95-100 +67.7 (c=0.26; CH3OH) 15 95-100 -66.5 (c=0.275; CH3OH) 16 200-201.5 - 17 215-216 - 18 230-232 +70.7 (c=0.825; CH3OH) 19 243-248 -74.26 (c=0.715;CH3OH) 20 225-227 - 21 150-151 22 196-197 - 23 153-154 - 24 270-272 - 25 175-185 +18.4 (c=0.091;CH3OH) 26 277-279 - 27 297-300 28 260-262 +50.53 (c=0.56; CH3OH) 29 109-111 - 30 236-238 +50.23 (c=0.325; CH3OH) 31 238-240 32 95-97 33 230-232 - 34 222-224 +70.9 (c=0.573; CH3OH) 35 258-259 - 36 234-235 - 84443 -34- 1306402 編號 熔點(°C) bB5 37 223-225 +80.7 (c=0.5; CH3OH) 38 217-219 -74.2 (c=0.51; CH3OH) 39 158-160 - 40 80-82 +67.3 (c=0.854; CH3OH) 41 124-126 - 42 210-212 +80.7 (c=0.896; CH3OH) 43 200-202 +71.7 (c=0.882; CH3OH) 44 259-260 - 45 256-258 +18.1 (c=1;CH3OH) 46 200-202 +79.7 (c=0.798; CH3OH) 47 79-81 - 48 216-218 +66.4 (c=l; CH3OH) 49 132 50 256-257 51 162-164 52 101-103 +57.9 (c=0.87; CH3OH) 53 234-236 54 110-112 55 199-201 56 94-96 57 141-143 +56.3 (c=0.59; CH3OH) 58 224-226 +74.90 (c=0.66; CH3OH) 59 138-140 84443 -35 - 1306402 編號 熔點(°C) bB5 60 104-106 +78.5 (c=0.57; CH3OH) 61 214-216 +54.8 (c=0.2; CH3OH) 62 135-137 +86.3 (c=0.5; CH3OH) 63 194-196 +61.5 (c=0.5; CH3OH) 64 149-151 65 199-201 66 221-223 67 167-169 68 255-257 69 126-128 70 100-102 71 121-123 使本發明之化合物接受一系列的藥理學試驗,證實其作 為具有治療活性之物質的重要性。 在表現天然人類運載者glvtl之SK-N-MC細胞中,運載甘胺 酸的研究
藉著在受試化合物的存在或缺乏下,測量併入的放射 性,在表現天然人類運載者glytl的SK-N-MC細胞(人類神經 上皮細胞)中,研究[14C]甘胺酸的捕捉。在預先以0.02%之 纖維網蛋白處理的培養盤上,以單層培養細胞48小時。在 實驗當天,移除培養基,並以pH 7.4之Krebs-HEPES([4-(2-羥乙基)六氫吡畊-1-乙烷磺酸]緩衝溶液沖洗細胞。在37°C 84443 -36- 1306402 下,在緩衝溶液(對照組)或各種濃度之受試化合物,或10 mM甘胺酸(判定非專一性的捕捉)的存在下,預先培養1 〇分 鐘之後,加入1 〇 uM [ C]甘胺酸(比活性112毫居里/毫莫 耳)。繼續在37 °C下培養1〇分鐘,並藉著以pH 7.4之 Krebs-HEPES緩衝溶液沖洗2次,使該反應中止。然後在加 入100微升液態閃爍劑並攪拌1小時之後,估計細胞併入的 放射性。在Microbeta TH-1uxtm計數器上進行計數。藉著 ICso,即降低50%甘胺酸之專一捕捉的化合物濃度,來判定 化合物的效力,IC5〇係藉著在由對照組併入之放射性和接受 1 OmM甘胺酸組之間的差異來定義。 在本測試中,本發明之化合物具有〇〇〇〇1至1〇 uM的 皇if Μ外研究化合物農捕捉『“Cl甘胺 酸的抑制活性 在實驗當天’藉著π服路徑(藉著在研料,以在蒸顧水 中0.5%之吐溫/Methocel頂的溶液濕冑受試分子來製備),或 藉者腹腔内·^隸(將受試分子溶解於生理鹽水巾,或藉著 在研钵中’以在水中〇.5%之吐溫/MethGeeiTM的溶液濕磨來 氣備依據刀子《冷解度而定),將漸增劑量之待研究的化 合物’投予20至25克的跑c“〇Fi雄性老鼠 '以媒劑處 理對照组。劑量按毫克/公斤計,根據待研究之分子,判定 投藥的路徑和處理的時間。 在投藥後一段特定的時間 ’將每隻動物的皮質迅速 ’或冷来在-80 °C下(在之 後 下 ’藉著斷頭人道地殺死動物之 地移至冰上,稱重並儲存在4七 兩種情況下,儲存試樣最多i 84443 • 37 - 1306402 天)。在PH 7.4之Krebs-HEPES緩衝溶液中,以1〇毫升/克組 織的比例,將每個試樣均質化。在室溫下,在1〇 mM L_丙 胺酸和缓衝溶液的存在下,培養每個勻漿各2〇微升1〇分 鐘。藉著在對照組中加入1 〇 mM甘胺酸,判定非專一性的 捕捉。藉著在真空下過濾,中止該反應,並藉著在Micr〇beta
Tri-lux计數器上計數,藉著固體閃爍現象,估計保留的 放射性。 [C]甘胺酸捕捉的抑制劑將降低併入每個勻漿内之放射 性配體的量。藉著其EDw ’即與對照組相比較,抑制5〇%[ιγ] 甘胺酸捕捉之劑量,來評估化合物的活性。 在本測試中,最有效的本發明化合物,藉著腹腔内路徑 或藉著口服路控,具有0.1至5毫克/公斤之ED5〇e 在老鼠脊髓勻漿中,研兜甘胺酸的遂来 藉著在待研究之化合物的存在或缺乏下,測量併入之放 射性,在老鼠脊髓勻漿中研究藉著運載者glyt2捕捉的[MC] 甘胺酸。 在已經人道地殺死動物之後(在實驗當天重2〇至25克的 Iffa Cx^do OF 1雄性老鼠),將每隻動物的脊髓迅速地移出, 稱重並儲存在冰上。在pH 7.4之Krebs-HEPES緩衝溶液 ([4-(2-羥乙基)六氫吡畊-丨·乙烷磺酸)中,以25毫升/克組織 的比例,將試樣均質化。 在25°C下,在pH7_4之Krebs-HEPES緩衝溶液和各種濃度 之待研咒的化合物,或1 〇 胺酸的存在下,預先培養 50微升勻漿1 〇分鐘,以便判定非專一性的捕捉。然後在25 84443 -38- 1306402 c下,加入[14C]甘胺酸(比活性=112毫居里/毫莫耳^❽分 鐘,至10 UM之終濃度。藉著在真空下過濾,中止該反應, 並藉著在MiCr〇beta Tri-lux™計數器上計數,藉著固體閃爍 現象,估計放射性。藉著能夠降低50%甘胺酸之專一捕捉 的濃度iCw,來判定化合物的效力,IC5〇係藉著在由對照組 併入之放射性和接受丨〇 mM甘胺酸組之間的差異來定義。 在本測試中,本發明之化合物具有0 000 i至丨0 直外研究化会物對於 酸的抑制法料
在實驗當天,藉著口服路徑(藉著在研砵中,以在蒸餾水 中0.5%之吐溫/Meth〇celTM的溶液濕磨受試化合物來製 備),或藉著腹腔内之路徑(將受試化合物溶解於生理鹽水 中,或藉著在研缽中,以在蒸餾水中05%之吐溫/MethocelTM 的溶液濕磨來製備),將漸增劑量之待研究的化合物,投予 20至25克的IffaCddoOFU^性老鼠。以媒劑處理對照組。 劑量按笔克/公斤計,根據待研究之化合物,判定投藥的路 徑、處理的時間’和人道殺死的時間。 在投藥後一段特足的時間,藉著斷頭人道地殺死動物之 後,迅速地移出脊髓,稱重並導入玻璃閃爍瓶中,儲存在 碎冰上,或冷凍在-80 C下(在這兩種情況下,儲存試樣最多 1天)。在?117.4之心^^-1^?£8緩衝溶液中,以25毫升/克組 織的比例,將每個試樣均質化。在室溫下’在緩衝溶液的 存在下’培養每個勻漿各5〇微升1〇分鐘。 藉著在對照組中加入10 mM甘胺酸,判定非專一性的捕 84443 -39- 1306402 捉。 藉著在真空下過濾,中止該反應,並藉著在Micr〇beta Td-1UXTM計數器上計數,藉著固體閃爍現象,估計放射性。 [C]甘胺酸捕捉的抑制劑將降低併入每個勻漿内之放射 性配體的量。藉著其EDw,即與對照組相比較,抑制5〇%[Mc] 甘胺酸捕捉的有效劑量’來評估化合物的活性。 在本測試中,最佳的本發明化合物,藉著腹腔内路徑或 藉著口服路徑,具有1至20毫克/公斤之ed5q。 對在其中r2代表一或多個卣素原子或三氟甲基基團的通 式⑴中,具有組悲(1 S,2S)之本發明化合物,及其具有組態 (1R,2R; 1S,2S)之蘇型消旋物進行試驗的結果,顯示它們在 試管内和在活體外’是出現在腦中之甘胺酸運載者办⑽ 抑制劑。 這些結果暗示本發明之化合物,可用來治療與病呆、精 神病有關的行為病症,特別是精神分裂症(缺陷型和產生 型),以及由精神安定藥(柳。响叫引起的急性和慢性雜 體外徵候群,用來治療各種類型的焦慮、恐慌發作、恐懼 症、強迫性病症’用來治療各種類型的抑f,包括精神病 陡抑營症用來治療因為酒精濫用或停用酒精所引起之病 、〖生仃為病纟&物攝取病症’以及用來治療偏頭痛。 對在其中R2代表!I素原予和胺基基團皿爪兩者的通式 ()中/、有JL .J (1R,2R)之本發明化合物,及其具有組態 (R’2R, 1S’2S)H物進行試驗的結果,顯示它們在試管 内和在活月&外①出現在脊髓中之甘胺酸運載者咖的抑 84443 -40- 1306402 制劑。 运些結果暗示本發明之化合物,可在風濕病學和在急性 脊髓病理學上,用來治療疼痛性肌肉攣縮,用來治療脊髓 或腦來源的痙攣性攣縮,用來對症治療溫和至中等強度的 急性和亞急性疼痛,用來治療強烈及/或慢性疼痛、神經原 性疼痛和難治療的疼痛,用來治療帕金森氏症,以及神經 變性來源或由精神安定藥引起的帕金森氏徵候群,用來治 療原發和繼發性全身性癲癇'具有簡單或複雜症狀學的部 分性癲癇、混合型和其他癲癇之症狀,作為其他抗癲癇治 療的補充,或以單一治療,用來治療睡眠呼吸暫停,並用 於神經保護。 因此,本發明之目標亦是醫藥组合物,其含有有效劑量 之至少一種根據本發明的化合物,並為在藥學上可接受的 驗或鹽或媒合物之形式,且在適當之處,為帶有適當賦形 劑之混合物的形式。 根據藥學劑量形式和想要的投藥模式,來選擇該賦形劑。 因此’根據本發明之醫藥组合物,可企圖供口服、舌下' 皮下、肌肉内、靜脈内、局部、氣管内、鼻内、經皮、直 腸或眼内投藥使用。 投藥之單位形式可以是,例如錠劑、明膠勝囊、顆粒、 散劑、口服或注射用溶液或懸浮液、貼片或检劑。至於局 部投藥,可能想像軟膏、洗劑和洗眼液。 根據蓋儉氏製劑之形式,該單位劑量含有容許每天投予 0 _ 01至2 0毫克活性成份每公斤體重的劑量。 84443 -41 - 1306402 欲製備錠劑,在活性成分中加入微粒化或相反的藥學媒 劑’其可包括稀釋劑’像是例如乳糖、微晶纖維素、殿粉 和么式化的佐劑,像是粘合劑(聚乙烯吡哈垸酮、幾丙基曱 基纖維素及其類似物)、促進流動劑,像是矽石、潤滑劑, 像是硬脂酸鐵、硬脂酸、三廿二垸酸甘油、硬脂酿反丁 晞一 納亦可加入濕潤劑或表面活性劑,像是十二燒基 硫酸鈉。 產製的技術可以是直接壓緊、乾式成粒作用、濕式成粒 作用或熱-模塑。 錠劑可以是未塗覆的、以例如薦糖塗覆的,或以各種聚 合物或其他適當材料塗覆的可藉著塗覆時所使用的聚合 物基質或特殊的聚合物,將其設計成可容許迅速、延遲或 延長地釋放活性成份。 欲製備明膠膠囊,將活性成分與乾的(簡單混合、乾式或 濕式成粒作用,或熱·模塑)、液體或半固體的藥學媒劑混合。 明膠膠囊可以是硬或軟的’塗覆薄膜或相反,而得以具 有迅速、延長或延遲的活性(例如腸道的形式)。 人以糖漿或酏劑形式之组合物,或是以滴劑形式投藥之组 :物’可含有活性成分,連同增甜劑,最好是無熱量的, 乍為防腐劑的對幾苯〒酸甲酉旨、對#苯甲酸丙醋、香味修 改劑和著色劑。 刀敢在水中的散劑 制,或諸如聚㈣料垸嗣之類的分散劑,以及與增街 和香味矯正劑形成混合物形式的活性成份。 印 84443 -42- 1306402 至於直腸投藥,使用在直腸溫度時融化之粘合劑,例如 可可脂或聚乙二醇來製備的栓劑。 關於非經腸投藥’使用含水的懸浮液、等張的鹽水溶液 或無菌注射用的溶液,含有在藥理學上可相容的分散劑及/ 或濕潤劑,例如丙二醇或丁二醇。 亦可以微膠囊之形式調配活性成分,可視需要連同—或 夕種載劑或添加物,或者帶有聚合物基質,或帶有環糊精 (貼片、延長釋放之形式)。 根據本發明之局部組合物,包括可與皮膚相容的介質。 特別是以含水的、含醇的或含水-含醇的溶液、凝膠、具有 乳相或凝膠外觀的油包水或水包油之乳劑、微乳劑、氣溶 、 形式或者以含有離子及/或非離子性脂質的囊泡分散 體 < 形式提供該介質。根據在所考慮之領域中慣用的方 去,來製備這些蓋倫氏製劑之形式。 瑕後,根據本發明之醫藥組合物,除了通式⑴之化合物 〈外’尚可含有其他可用來治療上文指示之病症和疾病的 活性成分。 84443 43-
Claims (1)
130濟赠09074號專利申請案 中丈甲'請專利範圍替換本(97年8月)I---------------------------- 拾、申請專利範圍: t?月$轉(楚).的| 1 · 一種通式(I)之化合物,呈纟屯的#風 ! 现的先學異構體(1R,2R)或 〇S,2S)之形式,或呈蘇型⑽叫非對映異構物之形式,
其中A代表 通式N-R,之基團,其中Ri代表氯原子,或直線或分支 的(CrC7)烷基基團,可視需要以一或多個氟原 或(CVC7)環烷基基團,或(c^C7)環烷基(cvc3)烷基基 團,或苯基(CrC:3)烷基基團,可視需要以一或二個羥基 或甲氧基基團取代,或(C2_C4)烯基基團或(C2_C4)炔基基 團, 或通式N+CCOR,之基團,其中Rl如同上文之定義, 或者是通式N+(R,)Rl之基團,其中R,代表直線或分支的 (C丨-C7)烷基基團,且r]如同上文之定義, X代表氫原子,或一或多個選自鹵素原子和三氟曱基、 直線或分支的(CrC4)烷基和(Ci-C4)烷氧基基團的取代 基, R·2代表氫原子’或一或多個選自鹵素原子和三氟曱 基、(CVC4)烧基或(C丨-C4)烧氧基基團,或通式nr3r4之胺 基基團’其中R3和R4彼此各獨立代表氫原子或(Ci_C4)烷 基基團’或與彼等所攜帶的敗原子形成p比洛D定、六氫叶匕 84443-970807.doc 1306402 咬或嗎啉環,或可視需要以根據針對上文符號又所定義之 原子或基團取代之苯基基團的取代基, 其以自由鹼,或酸加成鹽的形式存在。 2.根據申請專利範圍第丨項之化合物,其特徵在於a代表通 式N-R,之基團,其中 Ri代表氫原子; X代表氫原子,或一或多個選自鹵素原子和三氟甲基、 直線或分支的(C,-C4)烷基和(Q-C:4)烷氧基基團的取代 基; 尺2代表氫原子,或一或多個選自鹵素原子和三氟甲 基、(C丨-C4)烷基或(Cl_C4)烷氧基基團,或通之胺 基基團,纟中R3和R4彼此各獨立代表氫原?或(Cl-C4» 基基團,或與彼等所攜帶的氮原子形成吡咯啶、六氫吡 啶或嗎啉環’或可視需要以根據針對上文符號X所定義之 原子或基團取代之苯基基團的取代基。 根據申請專利範圍 第1項之化合物,其特徵在於A代表通 3. ,X為氣且R_2如申請專 式NR,的基團,其中R|為甲基基團 利範圍第1項所定義。 (根據中請專利範圍第i項之化合物,其特徵在於 態(1S,2S),且苴中尺冲矣々々 旁、J 基團。 〃中R2代表-或多個齒素原子或三氟" 5 .根據申請專利籍图楚,s 能nR2R、 化合物,其㈣在於其具有细 心、(1R,2R),且其中只 2弋表_素原子,或如申請專利範圍 84443-970807.doc l3〇64〇2 6 第1項中所定義的通式nr3r4之胺基基團。 •概辕申請專利範.圍第1項之化合物,其特徵在於其係選 列: 蘇-2-氯-N-[(l -乙基六氫吡啶-2-基)苯甲基]_3_三氣甲 基笨甲醯胺鹽酸鹽; 蘇-2-氣-N-[(l -乙基六氫吡啶-2-基)笨甲基]·3_三氟曱 基笨甲醯胺; 2、氯-N-[(1S)-[(2S)-1-曱基六氫吡啶-2-基]苯甲基]_3_三 氣甲基苯甲醯胺鹽酸鹽; 氣-N-[(1S)-[(2S)-1-曱基六氫吡啶-2-基]苯甲基]_3_三 氣曱基笨甲醯胺; 蘇-4-胺基-3-氯-正- [(1-甲基六氫吡啶_2_基)苯甲基]_5 三氟曱基苯甲醯胺鹽酸鹽; 蘇-4-胺基-3-氣-正- [(1-曱基六氫吡啶_2_基)苯曱基]_5 三氟曱基苯曱醯胺; 胺基-3-氣-N-[(1RM(2R)-1-甲基六氫吡啶_2_基]苯甲 基]-5-三氟甲基苯曱醯胺鹽酸鹽; 4_胺基-3-氯-Ν-ΚΙΚχρίΙΜ-曱基六氫吡啶_2基]苯甲 基]-5-三氟曱基苯甲醯胺; 蘇-2-氯-Ν-[苯基(六氫ρ比啶_2-基)甲基]_3_三氣甲基苯 曱醯胺鹽酸鹽; 蘇-2-氯-Ν-[苯基(六氫吡啶_2_基)甲基]_3_三氟甲基苯 甲醯胺; & 2-氯-N-[(S)-苯基-[(2S)_六氫吡啶_2_基]甲基]_3_(三氟 84443-970807.doc 1306402 甲基)苯甲醯胺鹽酸鹽; 2-氯-N-[(S)-苯基-[(2S)-六氫吡啶_2_基]甲基]·3_(三氟 曱基)苯甲醯胺; 氯-N-[[l-甲基-1-氧撐(oxid〇)_^氩吡啶_2_基](苯基) 曱基]-3-三氟曱基苯甲醯胺; (2S)-2[(lS)-[[2-氯-3-(三氟曱基)苯曱醯基]胺基](苯基) 曱基]-1,1-二曱基六氫p比旋峨。 一種用來治療與痴呆、精神病、精神分裂症(缺陷型和產 生型)有關的行為病症、用來治療各種類型的焦慮、用來 治療各種類型的抑誉(包括精神病性抑鬱症)、用來治療因 為酒精㈣或停用賴所引起之病症、性行為病症、食 物攝取病症、用來治療偏頭痛、用來治療強烈及/或慢性 疼痛、用來治療帕金森氏症、用來治療癲癇和其他癲癇 之症狀以作為其他抗癲癇治療的補充之醫藥組合物,其 特徵在於其包含與賦形劑併用之根據申請專利範圍第】 至6項中任一項的化合物。 8. -種根據申請專利範圍第i項之化合物之用途, 製造供下列之醫藥品:用來治療與痴呆、精神病、精神 分裂症(缺陷型和產生型)有關的行為病症;用來治療各種 類型的焦慮J用來治療各種類型的抑鬱,包括精神病性 抑鬱症;用來治療因為酒精濫用或停用酒精所引起 症、性行為病症、食物攝取病症;用來治療偏頭痛. 來治療強烈及/或慢性疼痛;用來治療帕金森氏症;用來 =療癲癎和其他癲痛之症狀’作為其他抗癲癇治療的補 84443-970807.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204916A FR2838739B1 (fr) | 2002-04-19 | 2002-04-19 | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200306830A TW200306830A (en) | 2003-12-01 |
TWI306402B true TWI306402B (en) | 2009-02-21 |
Family
ID=28686193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092109074A TWI306402B (en) | 2002-04-19 | 2003-04-18 | N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy |
Country Status (35)
Country | Link |
---|---|
US (2) | US7326722B2 (zh) |
EP (1) | EP1499589B1 (zh) |
JP (1) | JP4597532B2 (zh) |
KR (2) | KR101019313B1 (zh) |
CN (1) | CN100482646C (zh) |
AR (1) | AR039413A1 (zh) |
AT (1) | ATE361279T1 (zh) |
AU (1) | AU2003262420B2 (zh) |
BR (1) | BR0309397A (zh) |
CA (1) | CA2481461C (zh) |
CO (1) | CO5631432A2 (zh) |
CY (1) | CY1108025T1 (zh) |
DE (1) | DE60313602T2 (zh) |
DK (1) | DK1499589T3 (zh) |
EA (1) | EA007225B1 (zh) |
EC (1) | ECSP045369A (zh) |
ES (1) | ES2286444T3 (zh) |
FR (1) | FR2838739B1 (zh) |
HR (1) | HRP20040977B1 (zh) |
IL (2) | IL164400A0 (zh) |
IS (1) | IS2540B (zh) |
MA (1) | MA27192A1 (zh) |
ME (1) | MEP25608A (zh) |
MX (1) | MXPA04010326A (zh) |
NO (1) | NO329065B1 (zh) |
NZ (1) | NZ536015A (zh) |
PL (1) | PL373195A1 (zh) |
PT (1) | PT1499589E (zh) |
RS (1) | RS51888B (zh) |
SI (1) | SI1499589T1 (zh) |
TN (1) | TNSN04208A1 (zh) |
TW (1) | TWI306402B (zh) |
UA (1) | UA78025C2 (zh) |
WO (1) | WO2003089411A1 (zh) |
ZA (1) | ZA200408154B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842804B1 (fr) | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
FR2861073B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
FR2861074B1 (fr) * | 2003-10-17 | 2006-04-07 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
FR2861071B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique |
FR2861070B1 (fr) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique |
WO2005044810A1 (en) * | 2003-10-30 | 2005-05-19 | Janssen Pharmaceutica, N.V. | Glyt2 modulators |
CA2609972C (en) | 2004-03-22 | 2013-05-14 | Apkarian Technologies Llc | Method and compositions for treatment of chronic neuropathic pain |
JP4193949B2 (ja) * | 2005-04-08 | 2008-12-10 | ファイザー・プロダクツ・インク | I型グリシン輸送阻害剤としての二環式[3.1.0]ヘテロアリールアミド |
JP2009179562A (ja) * | 2006-08-11 | 2009-08-13 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害剤 |
FR2917735B1 (fr) * | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique |
TW200911808A (en) * | 2007-07-23 | 2009-03-16 | Astrazeneca Ab | Novel compounds |
EP2178842A2 (en) | 2007-08-22 | 2010-04-28 | Abbott GmbH & Co. KG | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use |
CN102083797B (zh) | 2008-04-01 | 2014-06-04 | Abbvie公司 | 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途 |
WO2010087761A1 (en) * | 2009-01-28 | 2010-08-05 | Astrazeneca Ab | 2-aza-bicyclo[2.2.2]octane compounds and uses thereof |
TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
JP5618047B2 (ja) * | 2010-01-29 | 2014-11-05 | 国立大学法人千葉大学 | ポジトロン断層撮影法およびポジトロン放出化合物 |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8778941B2 (en) | 2011-06-24 | 2014-07-15 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
MX2013015274A (es) | 2011-06-24 | 2014-03-31 | Amgen Inc | Anatagonista trpm8 y su uso en tratamientos. |
EP2739614B1 (en) | 2011-08-05 | 2017-02-22 | AbbVie Deutschland GmbH & Co KG | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY |
CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
FR2983197B1 (fr) * | 2011-11-29 | 2014-07-25 | Assist Publ Hopitaux De Paris | Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP3057958B1 (en) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
SG11201602982YA (en) | 2013-10-17 | 2016-05-30 | Abbvie Deutschland | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
US20170143681A1 (en) | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
FR3045044B1 (fr) * | 2015-12-11 | 2019-04-19 | Liphatech | Composition et appat rodonticide comprenant du flocoumafene, procede de lutte contre des rongeurs cibles nuisibles |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254569A (en) * | 1991-01-14 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | (Amidomethyl)nitrogen heterocyclic analgesics |
JP3026845B2 (ja) * | 1991-02-20 | 2000-03-27 | 日清製粉株式会社 | ピペリジン誘導体 |
US5524569A (en) | 1995-03-20 | 1996-06-11 | Rich; William A. | Anchor cover |
SK13092000A3 (sk) * | 1998-03-06 | 2001-03-12 | Janssen Pharmaceutica N. V. | Inhibítory prenosu glycínu, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie |
CA2406652A1 (en) * | 2000-04-20 | 2001-11-01 | Nps Allelix Corp. | Aminopiperidines for use as glyt-1 inhibitors |
-
2002
- 2002-04-19 FR FR0204916A patent/FR2838739B1/fr not_active Expired - Fee Related
-
2003
- 2003-04-15 AR ARP030101310A patent/AR039413A1/es unknown
- 2003-04-17 DE DE60313602T patent/DE60313602T2/de not_active Expired - Lifetime
- 2003-04-17 DK DK03740634T patent/DK1499589T3/da active
- 2003-04-17 ES ES03740634T patent/ES2286444T3/es not_active Expired - Lifetime
- 2003-04-17 RS YU91404A patent/RS51888B/en unknown
- 2003-04-17 JP JP2003586132A patent/JP4597532B2/ja not_active Expired - Fee Related
- 2003-04-17 KR KR1020087018794A patent/KR101019313B1/ko not_active IP Right Cessation
- 2003-04-17 UA UA20041008110A patent/UA78025C2/uk unknown
- 2003-04-17 EP EP03740634A patent/EP1499589B1/fr not_active Expired - Lifetime
- 2003-04-17 ME MEP-256/08A patent/MEP25608A/xx unknown
- 2003-04-17 SI SI200330893T patent/SI1499589T1/sl unknown
- 2003-04-17 PT PT03740634T patent/PT1499589E/pt unknown
- 2003-04-17 PL PL03373195A patent/PL373195A1/xx not_active IP Right Cessation
- 2003-04-17 CA CA002481461A patent/CA2481461C/en not_active Expired - Fee Related
- 2003-04-17 MX MXPA04010326A patent/MXPA04010326A/es active IP Right Grant
- 2003-04-17 EA EA200401172A patent/EA007225B1/ru not_active IP Right Cessation
- 2003-04-17 KR KR10-2004-7016718A patent/KR20040103973A/ko not_active Application Discontinuation
- 2003-04-17 AU AU2003262420A patent/AU2003262420B2/en not_active Ceased
- 2003-04-17 CN CNB038140063A patent/CN100482646C/zh not_active Expired - Fee Related
- 2003-04-17 US US10/511,886 patent/US7326722B2/en not_active Expired - Fee Related
- 2003-04-17 AT AT03740634T patent/ATE361279T1/de active
- 2003-04-17 IL IL16440003A patent/IL164400A0/xx unknown
- 2003-04-17 BR BR0309397-2A patent/BR0309397A/pt not_active IP Right Cessation
- 2003-04-17 WO PCT/FR2003/001232 patent/WO2003089411A1/fr active IP Right Grant
- 2003-04-17 NZ NZ536015A patent/NZ536015A/en not_active IP Right Cessation
- 2003-04-18 TW TW092109074A patent/TWI306402B/zh not_active IP Right Cessation
-
2004
- 2004-09-30 IS IS7479A patent/IS2540B/is unknown
- 2004-10-04 IL IL164400A patent/IL164400A/en not_active IP Right Cessation
- 2004-10-07 MA MA27892A patent/MA27192A1/fr unknown
- 2004-10-08 ZA ZA200408154A patent/ZA200408154B/en unknown
- 2004-10-14 CO CO04103284A patent/CO5631432A2/es not_active Application Discontinuation
- 2004-10-15 NO NO20044388A patent/NO329065B1/no not_active IP Right Cessation
- 2004-10-18 HR HR20040977A patent/HRP20040977B1/xx not_active IP Right Cessation
- 2004-10-18 EC EC2004005369A patent/ECSP045369A/es unknown
- 2004-10-18 TN TNP2004000208A patent/TNSN04208A1/fr unknown
-
2007
- 2007-04-03 US US11/695,912 patent/US20070197601A1/en not_active Abandoned
- 2007-07-24 CY CY20071100988T patent/CY1108025T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI306402B (en) | N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | |
JP4488891B2 (ja) | N−[フェニル(ピペリジン−2−イル)メチル]ベンズアミド誘導体、その製造法、およびその治療用途 | |
TW201301B (zh) | ||
US7750025B2 (en) | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | |
JP4181622B2 (ja) | 新規化合物 | |
PT1682503E (pt) | Derivados de n-( fenil ( alquilipiperidin-2il )mentil )benzamida, sua preparação e sua aplicação em terapêutica. | |
JP6929857B2 (ja) | 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド | |
TW200540142A (en) | New β-ketoamide compounds with MCH receptor antagonistic activity and medicaments comprising them | |
TW200940524A (en) | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | |
EP1735302B1 (en) | 4-amino-piperidine derivatives as monoamine uptake inhibitors | |
TW534906B (en) | Novel morpholine derivatives, process for preparing them and pharmaceutical compositions containing them | |
NO321149B1 (no) | (1-fenacy-3-fenyl-3-piperidylety)piperidinderivater, fremgangsmate for fremstilling derav og farmasoytiske preparater inneholdende de samme samt anvendelse | |
US20040097548A1 (en) | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | |
TW200524885A (en) | Morpholine derivatives as norepinephrine reuptake inhibitors | |
JPH04211059A (ja) | 新規なテトラヒドロピリジン誘導体 | |
WO2001046186A1 (en) | Benzofuran derivatives | |
JPH09505304A (ja) | 非ペプチド性タキキニン受容体拮抗物質 | |
JP2012517412A (ja) | N−[(6−アザビシクロ[3.2.1]オクト−1−イル)−アリール−メチル]−ベンズアミド誘導体、これらの調製およびこれらの治療的使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |